Seaport Therapeutics
PrivateLast Round
IPO
Apr 10, 2026
Est. Valuation
$733M
Total Funding Raised
$325M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Seaport Therapeutics is a biopharmaceutical company focused on developing innovative neuropsychiatric medicines that address significant patient needs while providing oral bioavailability to minimize side effects and enhance patient quality of life.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Mental Health, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Seaport Therapeutics Comparables
Compare Seaport Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neumora | 76% | |
| Sage Therapeutics | 76% | |
| Alto Neuroscience | 73% |
Seaport Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Apr 10, 2026 | ||||
| Series B | Oct 21, 2024 | ||||
| Series A | Apr 9, 2024 |
Key People
Founding team and executive leadership
Seaport Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CPP Investments | Series B |
| Invus Opportunities | Series B |
| ARCH Venture Partners | Series B, Series A |
| Foresite Capital | Series B |
| T. Rowe Price | Series B |
| PureTech Health | Series B, Series A |
| Invus | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 10, 2026
$100M raised in IPO round.
- Mar 26, 2026
New oral drug delivery technology developed with Monash University.
Recent news
Latest coverage and updates
- receives_financingSep 22, 2026
Seaport Therapeutics, Inc. received financing of $260M in initial public offering on May 1st '26.
- is_developingSep 9, 2026
Seaport Therapeutics, Inc. is developing GlyphAllo.
- attends_eventAug 31, 2026
Seaport Therapeutics, Inc. will attend event 21st Annual Wells Fargo Healthcare Conference on Sep 8th '26.
Seaport Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Seaport Therapeutics's valuation, stock price, and market status.
Is Seaport Therapeutics a public or private company?
Seaport Therapeutics is a private company.
What is the current stock price of Seaport Therapeutics?
Seaport Therapeutics is a private company with no public stock price. Caplight tracks Seaport Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Seaport Therapeutics worth (valuation)?
Seaport Therapeutics's valuation is estimated at $733.0M based on funding round data.
Can I buy Seaport Therapeutics stock?
Seaport Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Seaport Therapeutics's last funding round?
Seaport Therapeutics's most recent funding round was IPO on October 21, 2024.
Who are the main investors in Seaport Therapeutics?
Key investors in Seaport Therapeutics include ARCH Venture Partners, Foresite Capital, T. Rowe Price, General Atlantic, Sofinnova Investments.
Will Seaport Therapeutics IPO soon?
No public IPO plans have been announced for Seaport Therapeutics.
How can I track Seaport Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Seaport Therapeutics's secondary market activity and sign up for updates.